bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

Levi & Korsinsky Announces an Investigation on Behalf of bluebird bio, Inc. (BLUE) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

Lost Money on bluebird bio, Inc. (BLUE)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

Lost Money on bluebird bio, Inc.(BLUE)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

An analyst made a very deep price-target cut on the shares. He reduced his level by 56%.

Why Bluebird Bio Stock Dived Into the Red on Tuesday

It isn't often that you can find the right story at the right time to give you a good chance of multiplying your wealth; these so-called multi-bagger stocks get their name because their price sees a pop of more than 100%. Driven by a good story and other factors to help the jump happen.

bluebird bio Stock Signals Potential to be a Multi-bagger

Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT from CRISPR Therapeutics AG NASDAQ: CRSP and partner Vertex Pharmaceuticals Inc. NASDAQ: VRTX. CASGEVY made global headlines when it received FDA approval on December 8, 2023.However, on the same day, the FDA also approved LYFGENIA (lovotibeglogene autotemcel), which is another gene therapy treatment for SCD by bluebird bio NASDAQ: BLUE.

bluebird bio: How to play LEAPS options for growth and income

Maybe you are looking back at the 2020-2023 equity curve in your portfolio and are noticing an increasingly slowing upward trend. This is not your fault but rather the effects of the Federal Reserve (the Fed) raising interest rates, making ‘riskier' high growth plays less attractive to the overall market.

bluebird bio stock is ripe for a 400% institutional short squeeze

CRISPR Therapeutics

GoodRx Holdings

Gilead Sciences

Sarepta Therapeutics

Vertex Pharmaceuticals

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.

Gene therapy: Why does it cost millions for a single treatment?

Bluebird Bio's latest gene-editing therapy could have safety problems. The treatment's price also seems high compared to a notable competitor.

2 Red Flags for Bluebird Bio Stock

Sangamo Therapeutics

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.

2 low-priced gene therapy stocks to speculate on

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (the Company; bluebird) today announced updates to be presented at the 42nd Annual J.P. Morgan Healthcare conference including commercial launch progress, 2024 program milestones and financial outlook. Andrew Obenshain, chief executive officer, is scheduled to present Tuesday, January 9 at 10:30 a.m. PT/1:30 p.m. ET. “In 2023 bluebird cemented our status as a gene therapy leader, securing our third FDA approval in under two y.

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook

bluebird (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why bluebird (BLUE) Stock Might be a Great Pick

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30am PT/1:30pm ET. To access the live webcast of bluebird bio's presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.co.

bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Investors may be tempted to go bottom-fishing after BlueBird Bio's share price drawdown. However, competition from two rivals and a large stock offering should make investors think twice.

Should You Invest in Bluebird Bio Right Now?

Bluebird Bio has proven its innovative capabilities. However, the company likely won't turn a profit soon.

1 Green Flag and 1 Red Flag for Bluebird Bio Stock

By and large, biotech businesses tend to carry significant risks for investors. They're usually at risk of running out of money or their medicines not working.

3 Money-Saving Tricks for Investing in Biotech Stocks in 2024

bluebird (BLUE) issues shares to raise capital to support the commercialization and manufacturing of its three approved gene therapies. Its shares are down on the dilution of equity.

bluebird (BLUE) Stock Down on Raising Additional Capital

The plummeting share price is a potent symbol of the structural problems still facing small and midsize biotechs.

Bluebird Bio Stock Is in Free Fall

Biotech company bluebird bio Inc (NASDAQ:BLUE) has priced its underwritten public offering, making 83,333,333 shares of common stock available at $1.50 per share. The offering, expected to yield $125 million in gross proceeds, provides underwriters a 30-day option to purchase an additional 12,499,999 shares.

bluebird bio shares slide on pricing of $125M offering, FDA hurdles

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 83,333,333 shares of its common stock at a public offering price of $1.50 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a 30-day option to purchase up to an additional 12,499,999 shares of its common stock at the public offering price per share, less underwriting discounts and commission.

bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock to be sold in the offering. The offering, actual size and terms are subject to market conditions, and there can be no assurance as to whether or when the offerin.

bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

Bluebird Bio got one of its gene therapies approved recently. Its stock crashed due to certain contingencies associated with the approval.

Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?

bluebird bio Inc (NASDAQ:BLUE) shares took off on Thursday after the biotechnology company provided positive patient start guidance for the new year and revealed a commercial agreement with a U.S. payer that provides coverage to 100 million patients for its recently Food and Drug Administration (FDA)-approved sickle cell therapy Lyfgenia.

bluebird bio stock rises on 2024 patient start guidance; commercial agreement for sickle cell therapy

Bluebird bio said on Thursday a large insurer had agreed to cover its newly approved sickle cell disease gene therapy, easing some investor worries about resistance from other payers over the high price of the treatment.

Bluebird signs pact with insurer for sickle cell gene therapy

DISH Network

Nikola

Novocure

Plug Power

SolarEdge Technologies

SunPower

Wall Street loves a good comeback story. It's why analysts often put elevated price targets on severely beaten-down stocks.

News for bluebird bio Stock (BLUE)